BridgeMD
New treatment option for Coronary Artery Disease
Official title Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
ClinicalTrials.gov ID: NCT07582835
What this study is testing
What is Clopidogrel?
Clopidogrel is an investigational medicine, given as an once-daily, being studied as a potential treatment for coronary artery disease.
Also referred to as Plavix.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events. After an initial period of dual antiplatelet therapy, long-term treatment with a single P2Y12 inhibitor (such as clopidogrel, ticagrelor, or prasugrel) is often prescribed.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years
- Prior (≥3 months) ACS and/or PCI
- Eligible for P2Y12 inhibitor monotherapy after an uneventful DAPT course
- Free from ischemic (i.e. any new episode of ACS, symptomatic restenosis, stent thrombosis, stroke, any revascularization requiring prolonged DAPT)...
- Written informed consent.
You likely can't join if
- Unconscious patients
- Unable to provide written informed consent
- Under judicial protection, tutorship or curatorship
- Unable to understand and follow study-related instructions or unable to comply with study protocol
- Known hypersensitivity or allergy to clopidogrel, ticagrelor or prasugrel
- Severe hepatic impairment
See the full eligibility criteria
- Age ≥18 years
- Prior (≥3 months) ACS and/or PCI
- Eligible for P2Y12 inhibitor monotherapy after an uneventful DAPT course
- Free from ischemic (i.e. any new episode of ACS, symptomatic restenosis, stent thrombosis, stroke, any revascularization requiring prolonged DAPT) and/or bleeding events (defined as BARC ≥ 2) for at least 3 months
- Written informed consent.
- Unconscious patients
- Unable to provide written informed consent
- Under judicial protection, tutorship or curatorship
- Unable to understand and follow study-related instructions or unable to comply with study protocol
- Known hypersensitivity or allergy to clopidogrel, ticagrelor or prasugrel
- Severe hepatic impairment
- Haemoglobin level \<10 g/dL or platelet count \<100 000 cells/mL
- Pregnant or breastfeeding women
- Life expectancy less than 1 year
- Active participation in another treatment trial
- Need for concomitant oral anticoagulation
- History of intracranial haemorrhage (anytime), transient ischemic attack or stroke within 3 months
- PCI for in-stent restenosis or stent thrombosis at index PCI or within 6 months before randomization
The study team makes the final eligibility decision.
Where it's taking place
- Lugano, Ch/ti, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lugano, Ch/ti, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.